1. ALLA AKTIER
  2. NYHETER
  3. INITIATOR PHARMA

Initiator Pharma

Nyheter Initiator Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

INITIATOR PHARMA: Q3 2022 REPORT

MARKN.

Business highlights in Q3 2022

  • On July 5th the Company announced the outcome of the fully guaranteeed rights issue of MSEK 41. Approximately 42.3% of the share issue was subscribed for, with the rest covered by underwriting commitments.
  • On July 5th the Company announced that it had carried out a directed share issue of MSEK 2.5 at a share price of SEK 7.50 to a strategic advisor to the company.
  • On July 22nd the Company announced that it had completed a share buy back program of 24,000 shares in connection with the long-term incentive program LTI2021.
  • On September 21st the Company announced that the final study report from the Phase 1 study in the IPTN2021 program confirmed the statistically significant effects on pain measures that were reported after the first data read-out in May.

Business highlights after this reporting period

  • On October 4th the Company announced the outcome of the LTI2022 incentive programs to management and leading employees and to board members.
  • On November 4th the Company provided an update on its clinical programs.

Financial Highlights

Third Quarter (2022-07-01 – 2022-09-30)
Net revenue were TDKK 0 (0)
Operating loss, EBIT was TDKK -6,689 (-9,056)
Earnings per share was DKK –0.13 (-0.24)
Cash: TDKK 46,768 (41,394)
Solidity: 70% (92%)
First Nine Months (2022-01-01 – 2022-09-30)
Net revenues were TDKK 0 (0)
Operating loss, EBIT was TDKK -35,263 (-15,792)
Earnings per share was DKK –0.68 (-0.51)

Solidity: equity divided by assets.

The Board of Directors have decided that interim reports will be published in English only.

Link to the full report
https://www.initiatorpharma.com/en/investors/reports-and-presentations/

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage life science company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of three clinical programs - the drug candidates IP2018 and IPED2015 for treatment of erectile dysfunction of psychogenic and organic origin, respectively, and the orphan drug candidate IPTN2021 developed for Trigeminal Neuralgia, a severe neuropathic pain condition. 
 
Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Q3 2022 Initiator Ph Engelsk FINAL

Datum 2022-11-04, kl 08:30
Källa MFN
Bifogade filer
Q3 2022 Initiator Ph Engelsk FINAL